RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q2 FY24 results · Jul–Sep 2023
RPG Life Sciences reported revenue from operations of ₹153.58 crore (up 13.9% from Q2 FY23) and net profit of ₹25.86 crore (up 29.5% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a standalone basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 153.58 | 134.79 | +13.9% | 147.78 | +3.9% |
| Other income | 1.83 | 1.23 | +48.8% | 1.81 | +1.1% |
| Total income | 155.41 | 136.02 | +14.3% | 149.59 | +3.9% |
| Profit before tax | 34.79 | 27.01 | +28.8% | 29.77 | +16.9% |
| Net profit for the period | 25.86 | 19.97 | +29.5% | 22.10 | +17.0% |
| EPS, basic (₹) | 15.64 | 12.08 | +29.5% | 13.36 | +17.1% |
| Net margin (%) | 16.8 | 14.8 | 15.0 |
Standalone
- Filed with BSE
- 25 Oct 2023, 15:50 IST
- Board meeting
- 18 Oct 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE